After Oppenheimer and Cantor Fitzgerald gave Mesoblast Ltd (NASDAQ: MESO) a Buy rating last month, the company received another Buy, this time from Maxim Group. Analyst Jason McCarthy maintained a Buy rating on Mesoblast Ltd today and set a price target of $16. The company’s shares closed yesterday at $6.63.
McCarthy wrote:
“Mesoblast announced that is has expanded its existing partnership with TEMCELL commercialization partner, JCR Pharmaceuticals (4552 – NR) to a second indication, treatment of Epidermolysis Bullosa (EB) in Japan.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 8.2% and a 44.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Mesoblast Ltd has an analyst consensus of Strong Buy, with a price target consensus of $18.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.78 and a one-year low of $4.74. Currently, Mesoblast Ltd has an average volume of 83.75K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases.
